CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 726 enrolled
Drug / intervention
Sulphonylurea +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01278485
NCT01278485N/ACompleted
CompareCT.gov

Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects

Merck Sharp & Dohme LLC·observational·Posted Jan 19, 2011·Updated Jul 28, 2015

In Brief

An observational study evaluating Sulphonylurea and Metformn for Type 2 Diabetes Mellitus. Completed, enrolled 726 participants.

Detailed Summary

This is a multicenter, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with type 2 diabetes mellitus (T2DM) who have been treated with sulphonylurea (SU) monotherapy or SU + metformin (MF) combination therapy by their cardiologist, nephrologist, or family practice doctor for at least 6 months prior to study enrollment. The purpose of the study is to assess treatment patterns, goal attainment rates, long-term diabetes complication rates, and frequency and severity of hypoglycemic episodes among T2DM participants treated in cardiology, nephrology and family practice settings.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.5 years ago

Interventions

Sulphonylureadrug

SU administered according to usual practice.

Metformndrug

Metformin administered according to usual practice.